This company is transforming lives and isn’t looking back. As pioneers in immunotherapy, Aduro Biotech is transforming lives by discovering, developing, and commercializing immunotherapies that are making big changes in the treatment of challenging diseases like cancer. Collaborating with the Polsky Center’s Technology Commercialization and Licensing team, Aduro Biotech is paving the way with several leading-edge proprietary technologies designed to initiate and sustain the immune system to mobilize and attack tumors. With an extensive pipeline of three proprietary technology platforms — Live, Attenuated Double-Dated (LADD), STRING Pathway Activators, and B-select monoclonal antibodies –immunotherapies have been developed to target a variety of cancers as well as infectious and autoimmune diseases. Follow along with Aduro Biotech’s journey on LinkedIn as they look to continue changing the landscape of cancer care.
- Principal Investigator – Tom Gajewski
- Headquartered in Berkley, CA
- Deal Date- 2016
- Current Status- Phase I: Clinical Trial Launched